Metsera, Inc.
MTSR
Rank in Stocks
#2575
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Share Price
$70.50
Last synced: 2025-11-14
Market Cap
$7.33B
Change (1 day)
0.00%
Change (1 year)
33.60%
Country
US
Trade Metsera, Inc. (MTSR)
Category
Healthcare
Dividend yield history for Metsera, Inc. (MTSR)
Metsera, Inc. (stock symbol: MTSR) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Metsera, Inc. (MTSR) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
